You are here

Cancer cell DOI:10.1016/j.ccr.2009.04.012

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Publication TypeJournal Article
Year of Publication2009
AuthorsVasudevan, KM, Barbie, DA, Davies, MA, Rabinovsky, R, McNear, CJ, Kim, JJ, Hennessy, BT, Tseng, H, Pochanard, P, Kim, SY, Dunn, IF, Schinzel, AC, Sandy, P, Hoersch, S, Sheng, Q, Gupta, PB, Boehm, JS, Reiling, JH, Silver, S, Lu, Y, Stemke-Hale, K, Dutta, B, Joy, C, Sahin, AA, Gonzalez-Angulo, AM, Lluch, A, Rameh, LE, Jacks, T, Root, DE, Lander, ES, Mills, GB, Hahn, WC, Sellers, WR, Garraway, LA
JournalCancer cell
Volume16
Issue1
Pages21-32
Date Published2009/07/07
ISSN1535-6108
Abstract

Dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in PIK3CA mutant cancer cells. Thus, PI3K may promote cancer through both AKT-dependent and AKT-independent mechanisms. Knowledge of differential PI3K/PDK1 signaling could inform rational therapeutics in cancers harboring PIK3CA mutations.

URLhttp://linkinghub.elsevier.com/retrieve/pii/S1535-6108(09)00177-9
DOI10.1016/j.ccr.2009.04.012
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/19573809?dopt=Abstract